3.3MM shares as of 1045am. not too bad. price up now too. why can't PFE just offer $25 and be done with it!!!! I'd cream my pants
they'd put one or two chemists on ebola making compounds to cure the disease. they can just mix benzoic acid, HBTU and EtOH all day long and just say they are working on it. the stock would hit 15 the next day.
sell??? at what price. the market is saying this 26113 trial is bogus and junk. no jump in value for the company. if inclusig isn't what it's supposed to be and 26113 isn't squat, then it's the mystery pile of dogsheet that's left in the pipeline. man, how did this junk ever get to 25 is beyond me. MRK bought out idenix or something like that for 4.3B and they had preclinical compounds. geez, just burn the place down and be done with it. Denner - do something.
as far as a NDA, the buying company has to sign one since ARIA would be opening their data, books, files etc to the potential buyer to do their DD.
if denner's average is 3.80's like some say, selling at 17 or higher is a huge gain. Berger wants too much. Why can't he take the buyout and stay on to run the business with big pharma's deep pockets. ARIA has little cash to do good trials.
ACHN went from 7 in early august to 13 in the middle to end of august. nice gain. now it's 10.77 but still a good gain. I didn't read the press releases but could be approval or phIII data instead of our Ph doesn't matter data.
good news from a cancer candidate and it's up a few cents??? other stocks go up 50% in one day. this dog won't hunt. as for a buyout, someone said that the company has a duty to release the news whether or not they will accept the offer. so I doubt anyone has offered a penny for aria at this point. they don't have any great drugs worth the buyout.
sounds good. wish he'd read the boards but doubt he does. I'm wondering if anyone will take this out in the low 50's????
me too. I bought more to average down. all they need is one new indication or drug and we're over 20 in a few months.
so what. they just patented some compound that's in medchem most likely. like 6 years away from the market if it works. it could be an extension on an existing compound further along too. we need clinical trail data. otherwise, this isn't moving. there are lots of talks and buyouts in pharma. just not here. that might tell us something about their pipeline or lack thereof.
I told you 5 big pharmas gave my company millions and bought shares. the company is almost bust. they all lost and moved on. New hedge funds and investors moved in but they will lose too. So just because these guys bought, doesn't mean squat other than they had money and gave it away
they bundle sell orders till they get enough to cover the buy. it might take some time but the buyer waits and then they take all the sells and give them the shares.
give it up. the market is selling drilling companies like they did gold a couple of years ago. then they all rebounded 50% or more in 6 months.